Skip to main content
BiotoxtechCo.,Ltd. logo

BiotoxtechCo.,Ltd. — Investor Relations & Filings

Ticker · 086040 ISIN · KR7086040003 KO Professional, scientific and technical activities
Open in API
Filings indexed 172 across all filing types
Latest filing 2023-03-14 Proxy Solicitation & In…
Country KR South Korea
Listing KO 086040

About BiotoxtechCo.,Ltd.

http://eng.biotoxtech.com/

Biotoxtech Co., Ltd. is a non-clinical Contract Research Organization (CRO) that provides safety and efficacy evaluation services. The company offers a comprehensive suite of GLP-compliant studies, including general toxicity, carcinogenicity, reproductive and developmental toxicity, genotoxicity, immunotoxicity, and safety pharmacology. It also conducts efficacy evaluations and provides analytical research services such as pharmacokinetics (PK/TK/ADME) and bioanalysis. Biotoxtech serves a diverse clientele developing pharmaceuticals, biomedicines, cell and gene therapies, medical devices, chemicals, agrochemicals, cosmetics, and health functional foods.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a '주주총회소집공고' (Notice of Convocation of General Meeting of Shareholders) for BioToxTech. It contains the agenda for the upcoming Annual General Meeting (AGM), including items for approval such as financial statements, director appointments, and remuneration limits. It also includes detailed information regarding electronic voting procedures and management's business overview. This document is a standard proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes.
2023-03-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the shareholding status, changes in ownership, and collateral agreements of the major shareholder (Kang Jong-Koo) of Biotoxtech. This type of filing is a standard regulatory disclosure regarding significant share ownership and changes in control, which falls under the 'Major Shareholding Notification' category.
2023-03-02 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Biotoxtech. It outlines the date, location, agenda items (financial statement approval, board/auditor appointments, and remuneration limits), and details regarding the election of directors and auditors. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2023-02-28 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal notification filed by Biotoxtech regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date where many companies hold their AGMs). It explains the reasons for this scheduling conflict and provides details on the meeting date and notice date. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or the voting results, it falls under the general regulatory filing category.
2023-02-28 Korean
최대주주변경을수반하는주식담보제공계약해제ㆍ취소등
Major Shareholding Notification Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the cancellation or release of a stock collateral agreement involving the company's largest shareholder. This type of disclosure, which details changes in share collateralization and potential impacts on ownership, is classified as a regulatory filing (RNS) as it does not fit into specific categories like director dealings or share issues, but is a standard corporate disclosure.
2023-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Biotoxtech) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean stock market (DART system) for listed companies to provide preliminary financial results before the final audit report is finalized. Since it is an initial announcement of financial performance highlights rather than a full annual report or a simple report publication notice, it falls under the 'Earnings Release' category. FY 2022
2023-02-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.